AMRN News & Events

Amarin celebrated the recommendation that the treatment of CV risk in patients with hypertriglyceridemia be part of a broader dyslipidemia management as discussed in the 2026 American College of Cardiology, or ACC, / American Heart Association, or AHA,/Multisociety Dyslipidemia Guideline Update. These newly-issued, evidenced-based recommendations summarize the clinical role of icosapent ethyl in reducing cardiovascular, or CV, risk in statin-treated patients with elevated triglycerides, or TG, and fully align with Amarin's commitment to addressing the burden of CV disease across the healthcare ecosystem. The updated guideline reinforces that patients on statin therapy can experience residual CV risk driven by elevated TG levels - a significant clinical challenge affecting millions of Americans. Amarin's VASCEPA/VAZKEPA, or icosapent ethyl, is an effective, safe, oral therapy that has been prescribed more than 30M times globally.

Peter Fishman, Amarin's Chief Financial Officer, said, "Our fourth quarter performance reflects our early success in optimizing the Company's operations and creating what we believe is a more efficient platform for long-term growth. We realized $31 million of the expected $70 million in cost savings from our restructuring initiatives and have incurred nearly all of the $37 - $40 million in restructuring costs. Our cash position improved sequentially and year over year, ending 2025 with total cash and investments of $303 million and no debt. As a direct result of our continued revenue generation and new financial operating profile, our return to positive cash flow in the fourth quarter was ahead of schedule and has positioned us to generate positive cash flow for the full year ahead. We are well positioned to deliver on our operational and strategic priorities in 2026."